Monocyte Chemoattractant Protein-1− 2518 A/G Single Nucleotide Polymorphism Might Be Associated with Renal Disease and Thrombocytopenia of SLE

There is conflicting evidence on the contribution of the MCP-1 −2518 A>G (rs 1024611) polymorphism to SLE incidence and clinical manifestations. We examined the prevalence of the MCP-1 −2518 A>G polymorphism in SLE patients (n = 199) and controls (n = 250) in Poland. We did not observe a significant difference in the distribution of MCP-1 −2518 A>G polymorphic variants in patients with SLE and healthy individuals. However, we found an association between the GG versus AG and AA genotypes as well as the AG and GG versus AA genotypes with renal manifestations of SLE OR = 3.614 (1.123–11.631, P = 0.0345) and OR = 2.297 (1.301–4.057, P = 0.0046), respectively. We also observed that the MCP-1 AG and GG -genotypes contribute to the occurrence of thrombocytopenia in SLE patients OR = 2.618 (1.280–5.352, P = 0.0089). Our observations indicate that either MCP-1 −2518 G variant can be associated with some clinical findings in patients with SLE

A growing Medical Center

"The new Medical Center of the University is to have a five-story addition to house clinical research facilities of the School of Medicine. The addition is made possible by a grant of $375,000 from the National Institutes of Health division of the U.S. Department of Health, Education and Welfare."--Page

Clinical and genetic research of chronic glomerulonephritis

The paper presents data on interaction of candidate genes (S311C PON2, (-6)A/G AGT, (-1166)A/CAGTR1, (-592)C/A IL-10, VNTR IL-1Ra, T113M IL-9, K198N EDN1, (+46)G/A ADRB2, G/A GNB3 (rs.2301339)) with oligogenic and continuous characters of chronic glomerulonephriti

The effectiveness of glucocorticoid therapy in patients with chronic glomerulonephritis, depending on the polymorphic markers of cytokine genes

The paper presents the results of a study of interrelationships of polymorphic cytokine loci (rs1800629 TNFα, rs909253 Ltα, rs767455 TNFR1 and rs1800469 TGFβ-1) with the features of glucocorticoid therapy in patients with chronic glomerulonephriti

Glomerulonephritis and malignancy: A population-based analysis

Glomerulonephritis and malignancy: A population-based analysis.BackgroundAn association between glomerulonephritis and malignant tumors has previously both been found and discarded in clinical series, but to our knowledge never has been tested in a population-based setting.MethodsThe Danish Kidney Biopsy Registry includes all kidney biopsies performed from 1985. Using a unique personal identification number, each person in the registry to the National Population Registry and the Danish Cancer Registry were linked. Cancer occurrence after the biopsy was compared in patients with morphological, glomerular diseases with that of the general Danish population, taking into account sex, age, calendar period and time since biopsy, and the 95% confidence interval (95% CI) for the observed-to-expected rates was calculated, assuming a Poisson distribution. Cancer occurrence was stratified to <1 year, 1 to 4, and ≥5 years after a biopsy.ResultsA total of 102 de novo cancers were found in 1958 patients. These cancers represent a two- to threefold excess of the expected number at <1 and 1 to 4, but not ≥5 years after a biopsy. Non-Hodgkin's lymphomas were observed six to eight times more than expected. Cancer excess was seen in glomerulonephritides with a known or suspected virus etiology.ConclusionsThe excess cancer rate could be the result of underlying undiagnosed tumors whose antigens have initiated glomerulonephritis, or the immunosuppressive therapy that initiated or energized tumor cells. Based on the findings in our study, there is some support for an association to persistent viruses causing first the glomerulonephritides and then the malignancies, perhaps through a common pathogenesis. This calls for other studies to be done that are specifically designed to investigate this issue, with more data on patient characteristics and confounders

Genetic factors of decreased kidney function in patients with chronic glomerulonephritis

The article presents the results of studying the interaction of polymorphic variants of vascular homeostasis genes (I/D ACE, 4а/4b eNOS, S311C PON2, (-6) A/G AGT, (-1166) A/С AGTR1, G/A GNB3 (rs.2301339), G460W ADD1, (+46) G/A ADRB2, K198N EDN1, (+6986) G/A CYP3A5) with the state of renal function at the onset of chronic glomerulonephriti

IgA-Nephropathie: Die häufigste Glomerulonephritis-Form

Zusammenfassung: Die IgA-Nephropathie (IgAN) ist die weltweit häufigste primäre Glomerulopathie. Meist manifestiert sie sich in der Adoleszenz oder im frühen Erwachsenenalter als wiederkehrende Makrohämaturie (oft getriggert durch einen Infekt der oberen Atemwege bzw. starke körperliche Anstrengung) oder als persistierende Mikrohämaturie, milde Proteinurie, arterielle Hypertonie und/oder Niereninsuffizienz. Sie wird häufig zufällig diagnostiziert. Viele Fälle bleiben wahrscheinlich unentdeckt. In Autopsieserien wird häufig IgA in den Glomeruli nachgeweisen [3, 4], wobei es meist Ablagerungen sind ohne dass eine manifeste IgAN bestanden hat. Nahezu 30% der Patienten leiden an einer chronischen, langsam progredienten Niereninsuffizienz. Die hauptsächlichen prognostischen Faktoren für die Progression der Nephropathie sind der Schweregrad der Niereninsuffizienz zum Zeitpunkt der Diagnose, der Grad der Proteinurie und das Vorliegen einer arteriellen Hypertonie. Eine frühe Identifikation des Vorliegens von Risikofaktoren ist entscheidend, da durch gezielte therapeutische Maßnahmen das Fortschreiten der Niereninsuffizienz vermindert werden kann. Die Nierentransplantation ist trotz der Rezidivrate der IgAN (bis zu 40% innerhalb von 5 Jahren) eine gute Therapieoptio